CN116509902B - Probiotic agent for improving mental diseases caused by environmental pollution by adjusting intestinal-brain axis and application thereof - Google Patents
Probiotic agent for improving mental diseases caused by environmental pollution by adjusting intestinal-brain axis and application thereof Download PDFInfo
- Publication number
- CN116509902B CN116509902B CN202310249024.XA CN202310249024A CN116509902B CN 116509902 B CN116509902 B CN 116509902B CN 202310249024 A CN202310249024 A CN 202310249024A CN 116509902 B CN116509902 B CN 116509902B
- Authority
- CN
- China
- Prior art keywords
- probiotic
- environmental pollution
- improving
- strain
- bifidobacterium longum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 54
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 54
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 44
- 238000003912 environmental pollution Methods 0.000 title claims abstract description 36
- 208000020016 psychiatric disease Diseases 0.000 title claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 title abstract description 14
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 22
- 230000036506 anxiety Effects 0.000 claims abstract description 20
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 17
- 238000004321 preservation Methods 0.000 claims abstract description 17
- 230000001105 regulatory effect Effects 0.000 claims abstract description 5
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 12
- 229910052785 arsenic Inorganic materials 0.000 claims description 10
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 7
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- 239000012752 auxiliary agent Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 241001495180 Arthrospira Species 0.000 claims description 2
- 240000002900 Arthrospira platensis Species 0.000 claims description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 102000004407 Lactalbumin Human genes 0.000 claims description 2
- 108090000942 Lactalbumin Proteins 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 241000222355 Trametes versicolor Species 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 238000011109 contamination Methods 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229940082787 spirulina Drugs 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 2
- 241000186000 Bifidobacterium Species 0.000 claims 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 34
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 24
- 210000002966 serum Anatomy 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 16
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 abstract description 14
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 abstract description 14
- 238000010172 mouse model Methods 0.000 abstract description 14
- 229960003638 dopamine Drugs 0.000 abstract description 12
- 108090000174 Interleukin-10 Proteins 0.000 abstract description 10
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 10
- 210000004556 brain Anatomy 0.000 abstract description 10
- 210000004185 liver Anatomy 0.000 abstract description 10
- 239000002858 neurotransmitter agent Substances 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 5
- 239000005556 hormone Substances 0.000 abstract description 5
- 229940088597 hormone Drugs 0.000 abstract description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 4
- 230000004783 oxidative metabolism Effects 0.000 abstract description 4
- 229920000881 Modified starch Polymers 0.000 abstract description 3
- 239000004368 Modified starch Substances 0.000 abstract description 3
- 230000010482 emotional regulation Effects 0.000 abstract description 3
- 235000019426 modified starch Nutrition 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 56
- 241000894006 Bacteria Species 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 229910001385 heavy metal Inorganic materials 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 230000036651 mood Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003344 environmental pollutant Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000012048 forced swim test Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000006872 mrs medium Substances 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 240000000103 Potentilla erecta Species 0.000 description 2
- 235000016551 Potentilla erecta Nutrition 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006400 anxiety behaviour Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007267 depressive like behavior Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XYJODUBPWNZLML-UHFFFAOYSA-N 5-ethyl-6-phenyl-6h-phenanthridine-3,8-diamine Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2N(CC)C1C1=CC=CC=C1 XYJODUBPWNZLML-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000196322 Marchantia Species 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000007529 anxiety like behavior Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000007175 bidirectional communication Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- -1 cysteine amino acid salt Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 229910021397 glassy carbon Inorganic materials 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 238000000444 liquid chromatography-electrochemical detection Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000007150 microbiota gut brain axis Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000006776 neuronal homeostasis Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 description 1
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a probiotic agent for improving mental diseases caused by environmental pollution by regulating intestinal-brain axes and application thereof, wherein strains in the probiotic agent comprise bifidobacterium longum Bifidobacterium longum BL strain with the preservation number of CGMCC No. 10452. The invention creatively discovers that BL21 strain has the effect of remarkably improving mental diseases caused by environmental pollution, and is specifically expressed in the following steps: improving liver oxidative metabolism level of environmental pollution mouse model, improving anxiety and depression-like mouse symptoms caused by environmental pollution, improving serum corticosterone content of environmental pollution mouse model, improving hormone level of organism, improving serum TNF-alpha, IL-6 and IL-10 cytokine level of environmental pollution mouse model, and improving brain neurotransmitter 5-HT and dopamine content. Therefore, the application of the modified starch has good application prospect in preparing products for preventing, relieving or treating emotion regulation.
Description
Technical Field
The invention belongs to the technical field of probiotics, relates to a probiotic for improving mental diseases caused by environmental pollution by adjusting an intestinal-brain axis and application thereof, and in particular relates to a probiotic for improving mental diseases caused by heavy metal pollution by adjusting an intestinal-brain axis and application thereof.
Background
With the progress of industry and technology, the generation of various environmental pollutants has greatly increased. Although pollution has a well-known impact on public health, little is known about the link between environmental pollutants, dysbacteriosis in the intestinal tract and mental health. Humans are exposed to a wide variety of contaminants in daily life, such as phthalates, heavy metals, bisphenol a, and air particulates, which have been identified as neurotoxic, that affect our gut microbiota and manipulate the bi-directional communication between the gut and brain, resulting in susceptibility to mental or nervous system disease, affecting our overall neurological and psychological health. Studies have shown that exposure to environmental pollutants may be an important variable risk factor for depression, anxiety, for example, the effects on synaptic transmission, dopaminergic system, glucocorticoid signaling and hypothalamic-pituitary axis may all be potential interfering mechanisms.
In recent years, microbiota has been the focus of research to find a missing link between neurological health and gut flora imbalance. More than 98% of the bacteria in the human intestinal tract are from four phylum, bacteroides, firmicutes, proteus and actinomycetes, constituting the complexity and diversity of microbiome. The involvement of microbiota in the central nervous system is mediated primarily by neurological, hormonal and immunological pathways, all of which are interrelated. Microorganisms can affect the central nervous system bi-directionally through the vagus nerve, regulate the activity of the HPA axis through the immune system, including plasma levels of glucocorticoids, tryptophan metabolism, neurotransmitter and neurotrophic factor production, expression and conversion, and the production of metabolites with neuroactive properties, such as short chain fatty acid SCFA. Short chain fatty acids can regulate the level of neurotrophic factors, promote neurogenesis, affect glial cell morphology and function, promote serotonin formation and improve neuronal homeostasis and function, and can alter the pathophysiology of cognitive, emotional and psychiatric disorders directly or indirectly. The presence of microbiota-gut-brain axis suggests that the gut microbiota composition and number will change, affecting the central and gut nervous systems, by different environmental pollutants. The disturbance of the intestinal flora caused by exposure to environmental pollutants may be a direct factor affecting the normal functioning of the brain and lead to mental health problems such as depression, anxiety and mood disorders.
CN114081184a discloses a probiotic agent for preventing depression and anxiety behavior formation and application thereof, and the provided 3 strains of lactobacillus plantarum Lp3a, lactobacillus paracasei LPC45 and bifidobacterium breve BB033 can produce neurotransmitters or precursor substances thereof, which can make people produce pleasant emotion, and galacto-oligosaccharide and isomaltooligosaccharide promote proliferation of beneficial bacteria, so that the beneficial bacteria produce neurotransmitters which make people pleasant, and meanwhile, the probiotic composition and functional substances can regulate intestinal health and supplement each other, thereby achieving the purpose of regulating emotion of human body, and further improving the effect of improving depression and anxiety symptoms. CN109310717a discloses a composition comprising a probiotic selected from the group consisting of lactococcus lactis and a combination of bifidobacterium longum and lactobacillus rhamnosus, preferably a combination of a lactococcus lactis strain or a lactobacillus rhamnosus LPR strain and a bifidobacterium longum BL999 strain, for use in the prevention and/or treatment of anxiety disorders and related disorders, such as chronic stress, depression and mood regulation in a mammal.
The use of probiotics to control intestinal microbiota is an effective treatment or prevention measure, can counteract behavioral and cognitive defects, can be used as a new action target for regulating intestinal brain axis and improving nervous diseases such as depression, anxiety, insomnia and the like, is a very healthy treatment scheme, and has wide market application prospect. Therefore, it is significant to develop more probiotic products to improve neurological disorders such as insomnia, anxiety, depression, etc.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a probiotic agent for improving mental diseases caused by environmental pollution through adjusting an intestinal-brain axis and application thereof, in particular to a probiotic agent for improving mental diseases caused by heavy metal pollution through adjusting an intestinal-brain axis and application thereof.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
in a first aspect, the present invention provides a probiotic for improving psychotic disorders caused by environmental pollution by modulating the intestinal-brain axis, wherein the strain in the probiotic comprises bifidobacterium longum Bifidobacterium longum BL strain with the preservation number of CGMCC No. 10452.
The invention creatively discovers that the bifidobacterium longum Bifidobacterium longum BL strain with the preservation number of CGMCC No.10452 has the effect of remarkably improving mental diseases caused by environmental pollution, and is specifically expressed in the following steps: (1) The liver oxidative metabolism level of the environmental pollution mouse model is obviously improved; (2) The anxiety and depression-like mouse symptoms caused by environmental pollution are obviously improved; (3) The serum corticosterone content of the environmental pollution mouse model is obviously improved, and the body hormone level is improved; (4) Significantly improving the serum TNF-alpha, IL-6 and IL-10 cytokine levels of an environmental pollution mouse model; (5) Is involved in the regulation of intestinal and brain axes of the organism, and improves the 5-HT and dopamine content of brain neurotransmitters. Therefore, the application of the modified starch has good application prospect in preparing products for preventing, relieving or treating emotion regulation.
In addition, bifidobacterium longum is a probiotic, and thus is highly safe and less prone to developing resistance when used in the preparation of products related to the prevention, alleviation or treatment of mood regulations.
Preferably, the mental disorders include anxiety, depression, insomnia.
Preferably, the environmental pollution comprises heavy metal pollution.
Preferably, in the probiotic agent, the viable count of the bifidobacterium longum Bifidobacterium longum BL strain is not less than 5×10 9 CFU/mL, e.g. 5X 10 9 CFU/mL、8×10 9 CFU/mL、1×10 10 CFU/mL、3×10 10 CFU/mL、5×10 10 CFU/mL、1×10 11 CFU/mL、1×10 12 CFU/mL, etc.; within the numerical rangeOther specific point values are selectable, and will not be described in detail herein.
Preferably, the strain in the probiotic agent further comprises a lactobacillus paracasei Lactobacillus paracasei LC strain with a preservation number of CGMCC No. 24411.
The invention also creatively discovers that the lactobacillus paracasei Lactobacillus paracasei LC strain with the preservation number of CGMCC No.24411 and the bifidobacterium longum Bifidobacterium longum BL strain with the preservation number of CGMCC No.10452 are compounded, and the lactobacillus paracasei Lactobacillus paracasei LC strain and the bifidobacterium longum Bifidobacterium longum BL strain can be matched and promoted mutually, and the effects of improving mental diseases caused by environmental pollution are synergistic. Compared with single bacteria, the combination mode of the two methods is more remarkable in the efficacy, the technical effect which is difficult to be predicted by the person skilled in the art is obtained, and a new strategy is provided for improving mental diseases caused by environmental pollution.
In addition, lactobacillus paracasei is a probiotic, so that it is highly safe and not prone to developing drug resistance when used in the preparation of products related to the prevention, alleviation or treatment of mood regulations.
Preferably, the ratio of the viable count of the bifidobacterium longum Bifidobacterium longum BL strain to the viable count of the lactobacillus paracasei Lactobacillus paracasei LC strain is 1:5-5:1, for example, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, etc., and other specific values within the above numerical ranges may be selected, which will not be described in detail herein.
When two strains are compounded in the specific proportion mode, the effect of improving the mental diseases caused by environmental pollution is more remarkable, namely the effect of the following effects is more remarkable: (1) Improving the liver oxidative metabolism level of the environmental pollution mouse model; (2) Improving anxiety and depression-like mouse symptoms caused by environmental pollution; (3) Improving the serum corticosterone content of the environmental pollution mouse model and improving the hormone level of the organism; (4) Improving the serum TNF-alpha, IL-6 and IL-10 cytokine levels of the environmental pollution mouse model; (5) improving brain neurotransmitter 5-HT and dopamine levels.
Preferably, the formulation of the probiotic agent comprises freeze-dried powder, capsules, tablets or granules.
The formulation of the probiotics related to the invention is not limited, and comprises the most commonly used freeze-dried powder, or further prepared capsules, tablets or granules. The lyophilized powder can be prepared by the following method:
inoculating a bifidobacterium longum BL21 strain or a lactobacillus paracasei LC24 strain into a culture medium for culture to obtain a culture solution; centrifuging the culture solution to obtain thalli; re-suspending the thalli by using a freeze-drying protective agent to obtain re-suspension; lyophilizing the resuspension to obtain the final product; or the two are compounded according to the proportion.
Preferably, the medium includes an MRS medium.
Preferably, the MRS medium includes, in concentration: 8-12g/L peptone, 8-12g/L beef extract, 15-25g/L glucose, 1-3g/L sodium acetate, 3-7g/L yeast powder, 1-3g/L, K of diammonium citrate 2 PO 4 ·3H 2 O 2-3g/L、MgSO 4 ·7H 2 O 0.05-0.2g/L、MnSO 4 0.01-0.1g/L, tween 80 0.5-2mL/L, cysteine hydrochloride 0.1-1g/L.
Preferably, the lyophilization is by vacuum freezing.
Preferably, the probiotic agent further comprises a lyoprotectant and/or a functional adjuvant.
Preferably, the lyoprotectant comprises any one or a combination of at least two of skim milk, gelatin, dextrin, acacia, dextran, sodium alginate, polyvinylpyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol.
Preferably, the functional auxiliary agent comprises any one or a combination of at least two of fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide, soy oligosaccharide, inulin, spirulina, arthrospira, coriolus versicolor polysaccharide, stachyose, polydextrose, alpha-lactalbumin or lactoferrin.
The functional auxiliary agent, namely the prebiotic, can be matched with the strain to play a role, so that the effect of the probiotic agent on improving mental diseases caused by environmental pollution is further improved.
In a second aspect, the present invention provides the use of a probiotic according to the first aspect in the manufacture of a medicament for the prevention, alleviation or treatment of psychotic disorders caused by environmental pollution.
In a third aspect, the present invention provides the use of a probiotic according to the first aspect in the manufacture of a medicament for the prevention, alleviation or treatment of anxiety or depression caused by heavy metal contamination.
Compared with the prior art, the invention has the following beneficial effects:
the invention creatively discovers that the bifidobacterium longum Bifidobacterium longum BL strain with the preservation number of CGMCC No.10452 has the effect of remarkably improving mental diseases caused by environmental pollution, and is specifically expressed in the following steps: (1) The liver oxidative metabolism level of the environmental pollution mouse model is obviously improved; (2) The anxiety and depression-like mouse symptoms caused by environmental pollution are obviously improved; (3) The serum corticosterone content of the environmental pollution mouse model is obviously improved, and the body hormone level is improved; (4) Significantly improving the serum TNF-alpha, IL-6 and IL-10 cytokine levels of an environmental pollution mouse model; (5) Is involved in the regulation of intestinal and brain axes of the organism, and improves the 5-HT and dopamine content of brain neurotransmitters. Therefore, the application of the modified starch has good application prospect in preparing products for preventing, relieving or treating emotion regulation.
The invention also creatively discovers that the lactobacillus paracasei Lactobacillus paracasei LC strain with the preservation number of CGMCC No.24411 and the bifidobacterium longum Bifidobacterium longum BL strain with the preservation number of CGMCC No.10452 are compounded, and the lactobacillus paracasei Lactobacillus paracasei LC strain and the bifidobacterium longum Bifidobacterium longum BL strain can be matched and promoted mutually, and the effects of improving mental diseases caused by environmental pollution are synergistic. Compared with single bacteria, the combination mode of the two methods is more remarkable in the efficacy, the technical effect which is difficult to be predicted by the person skilled in the art is obtained, and a new strategy is provided for improving mental diseases caused by environmental pollution.
Drawings
FIG. 1 is a graph of the time statistics spent in the open and closed arms by groups of mice;
FIG. 2 is a graph showing the statistics of the stationary time during swimming in each group of mice;
FIG. 3 is a graph showing the results of detecting reactive oxygen species ROS levels in the liver by the fluorescent dye DHE of mice of each group;
FIG. 4 is a graph showing statistical results of serum corticosterone concentration in each group of mice;
FIG. 5 is a graph showing statistics of serum TNF- α, IL-6, IL-10 levels from mice in each group;
FIG. 6 is a graph showing statistics of serotonin 5-HT and dopamine levels in prefrontal cortex tissue of mice in each group.
Detailed Description
The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the invention and are not to be construed as a specific limitation thereof.
Peptone, beef extract, glucose, sodium acetate, yeast powder, diammonium hydrogen citrate, K, as referred to in the examples below 2 PO 4 ·3H2O、MgSO 4 ·7H 2 O、MnSO 4 Tween 80 and cysteine hydrochloride were purchased from national pharmaceutical group chemical Co.
The following examples relate to the following media:
MRS Medium (g/L): 10g/L peptone, 10g/L beef extract, 25g/L glucose, 2g/L sodium acetate, 5g/L yeast powder, 2g/L, K diammonium hydrogen citrate 2 PO 4 ·3H 2 O 2.6g/L、MgSO 4 ·7H 2 O 0.1g/L、MnSO 4 0.05g/L, tween 80 1mL/L, cysteine amino acid salt 0.5g/L.
The bifidobacterium longum according to the following examples is named bifidobacterium longum Bifidobacterium longum BL strain, the preservation unit is China general microbiological culture Collection center, the preservation time is 2015, 01 and 27 days, the preservation number is CGMCC No.10452, and the address is: no.1 and No. 3 of the north cinquefoil of the morning sun area of beijing city.
The Lactobacillus paracasei related to the following examples is named Lactobacillus paracasei Lactobacillus paracasei LC strain, the preservation unit is China general microbiological culture Collection center, the preservation time is 2022, 02 and 21 days, the preservation number is CGMCC No.24411, and the addresses are: no.1 and No. 3 of the north cinquefoil of the morning sun area of beijing city.
The bacterial suspensions referred to in the following examples: inoculating each strain into skimmed milk, and culturing at 37deg.C for 18 hr for activation to obtain activating solution; inoculating the activating solution into MRS liquid culture medium according to the inoculum size of 2% (v/v), and culturing at 37 ℃ for 18h to obtain bacterial solution; diluting to obtain the final product.
Examples
This example investigated the effects of probiotics on the regulation of liver reactive oxygen species ROS levels, serum corticosterone levels, serum cytokines, serotonin 5-HT and dopamine levels, anxiety-like behavior, depression-like behavior in heavy arsenic contaminated mouse models:
(1) Grouping animals, establishing a heavy metal arsenic pollution mouse model and a dosing mode:
healthy C57BL/6 male mice (about 6 weeks old) were supplied by Shanghai laboratory animal centers and given regular granular rodent diet and purified water. All procedures involving mice were in accordance with guidelines provided by the Shanghai laboratory animal Care and animal Experimental center (license number 2022122004).
A total of 50 mice (10 mice/group, body weight 20.+ -.3 g), temperature 23-25 ℃, humidity 50-70% were placed in static micro-isolator cages of heat treated hardwood bedding for 12h light/dark cycles. Sodium arsenite (Fisher Scientific, MA, as 10 ppm) was administered to mice in drinking water for 4 weeks (about 8 weeks old) every monday and thursday to establish a model group; control (CTL) mice received purified water only; probiotic BL21 intervention group (BL 21 group) mice were also given BL21 bacterial liquid (1×10) daily on the basis of arsenic-containing water 9 CFU/day); probiotic LC24 intervention group (LC 24 group) mice were also given LC24 bacterial liquid (1×10) daily on the basis of arsenic-containing water 9 CFU/day); mice of the composite probiotic intervention group (BL 21+ LC24 group) were also given LC24 bacterial liquid (0.5X10) daily on the basis of arsenic-containing water 9 CFU/day) and BL21 bacterial liquid (0.5X10) 9 CFU/day).
(2) Four weeks after dosing, mice were tested for anxiety behaviour using the overhead plus maze: overhead cross fanThe uterus consists of two closed arms and two open arms (height 45cm; full arm length 66cm; arm width 10cm; closed arm wall height 30 cm). The mice were placed in the region of the central arm intersection (10X 10cm 2 ) And allowed to explore freely in the maze for 10min. The maze was cleaned with 70% ethanol after each test. The camera was mounted on the center ceiling of the maze for recording. The time the mice spent in the open and closed arms was recorded.
The statistical results are shown in fig. 1, and can be seen from the graph: compared with the CTL group, the time for the MC group mice to stay in the closed arm is obviously prolonged, namely the MC group mice have anxiety, after the probiotics BL21 are dried, the symptoms of the anxiety mice are relieved, the relieving degree of the compound bacteria intervention is more obvious, and the time for the mice to stay in the closed arm is obviously shortened; in contrast, the time that the mice of the MC group remained in the open arm was significantly shortened, indicating that anxiety-like neurological problems occurred in heavy metal-contaminated mice, but anxiety was significantly alleviated after probiotic BL21 intervention, and the extent of remission of the compound bacterial intervention was more pronounced (data in the figure were statistically analyzed using the R-language (R4.2.2) ggplot2 function, representing p <0.0001, representing p <0.001, and representing p < 0.05) compared to the MC group of the model group.
(3) Four weeks after dosing, mice were assessed for depressive-like behaviour using the Forced Swim Test (FST): putting the mice into a transparent acrylic cylinder (height 30cm; inner diameter 10 cm) with water depth 15cm (25 ℃) for swimming 6min in the first day; after swimming, the mice were wiped dry with paper towels and returned to their cages; the following day, the mice were swimming for the second time for 5min; swimming was recorded by a camera and behavior was analyzed by EthoVision video tracking software. The immobility time of the mice swimming was recorded.
The statistical results are shown in fig. 2, and can be seen from the graph: compared with the CTL group, the swimming time of the mice in the MC group is prolonged, depression symptoms appear, namely heavy metal arsenic pollution can cause the mice to appear depression-like mental diseases, but after the mice are subjected to the dry prognosis of probiotics BL21, the time for depression of the mice is shortened, namely the depression symptoms of the mice with diseases are improved, and the improvement degree of the intervention of compound bacteria is more remarkable (the data in the figure is statistically analyzed by using an R language (R4.2.2) ggplot2 function, and compared with the MC group in the model group, p is represented by p <0.0001, p is represented by p <0.001, and p is represented by p < 0.05).
(4) Mouse liver index detection: mice were sacrificed by anesthesia after the end of the experiment. OCT (optimal cutting temperature compound) embedded liver tissue was cut into 4 μm thick sections. Liver tissue sections were incubated with 5. Mu.M dihydroethidium DHE at 37deg.C for 30min in the dark, red ethidium oxide fluorescence was observed, and the reactive oxygen species ROS level in the liver was detected using the fluorochrome DHE, with the darker red reactive oxygen species ROS level being higher, and the results are shown in FIG. 3.
Arsenic and its compounds are accumulated in a large amount in blood after entering the body, and arsenic is gradually distributed to various tissue organs of the whole body along with blood circulation, and liver is a main target organ for arsenic accumulation in the body, as can be seen from fig. 3: the liver of the arsenic-contaminated mice is changed in pathological histology to different degrees, the liver injury of the arsenic-contaminated mice can be improved by the intervention of the probiotics BL21, the oxidation stress level is reduced, and the reduction of the oxidation stress level is more obvious by the intervention of the compound bacteria.
(5) Test of serum corticosterone content in mice: in the FST test, the mice were subjected to orbital sinus hemostix to obtain a basal state sample before swimming was started. Then, the mice were forced to swim for 6min and returned to their cages. After 30min, blood samples were collected again to obtain stress state samples. Serum was first diluted and assayed for corticosterone concentration using a commercial CORT EIA kit (marchantia purity biotechnology limited). The corticosterone concentration was analyzed using the criteria provided in the kit according to the manufacturer's instructions.
The statistical results are shown in fig. 4: compared with the CTL group, the blood corticosterone level of the MC group disease mice is obviously improved under the basic and stress states, but the corticosterone level of the anxiety mice is effectively reduced to the normal level close to the normal level of the CTL group mice after the intervention of probiotics BL21 or complex bacteria. Corticosterone is a glucocorticoid among adrenal corticoids secreted by the adrenal glands and plays an important role in coping with stress, also called stress hormone. Anxiety stress may lead to increased corticosterone, and probiotic administration may be effective in improving the mental state of anxiety mice due to environmental pollution, and modulating corticosterone levels by improving hormone secretion or metabolic dysfunction in anxiety mice (data statistically analyzed using the R language (R4.2.2) ggplot2 function in the figure, representing p <0.0001, representing p <0.001, and representing p < 0.05) compared to the model MC group).
(6) Mouse serum cytokine detection: after the end of the test, the mice were dissected, the serum was first diluted, and the tumor necrosis factor TNF-alpha, interleukin IL-6 and IL-10 content of each group was measured using ELISA kit (Wohan purity Biotechnology Co., ltd.) according to the manufacturer's instructions.
The statistical results are shown in FIG. 5, comparing the CTL groups, we found that the serum TNF-. Alpha.and IL-6 levels were significantly increased while the serum IL-10 levels were decreased in MC mice. In combination with prior studies, patients with depression typically have elevated serum levels of TNF- α, IL-6, and patients with major depression have higher ratios of TNF- α, IL-6 to IL-10 and lower serum IL-10 levels than patients without major depression. Our study showed similar results, i.e. depressed mice contaminated with heavy metals had a tendency to induce pathology of the immune system, with the rise in serum pro-inflammatory TNF- α, IL-6 levels and the decrease in anti-inflammatory IL-10 levels in the disease mice reversed by probiotic BL21 and complex bacterial stem prognosis, and the reversal of complex bacterial was more pronounced (data in the figure were statistically analyzed using the R-language (R4.2.2) ggplot2 function, representing p <0.0001, p <0.001, p <0.05 compared to the model MC group).
(7) Determination of serotonin 5-HT and dopamine content in mice: after dissection of the mice, the brain forehead cortex tissue was homogenized with a micro-sonicator (Q125 sonicator; qsonic, USA). The homogenized sample was then centrifuged at 12,000g for 10min at 4 ℃. The supernatant was filtered using a 0.22mm polyvinylidene fluoride membrane (4 mm syringe filter; millex-GV). After appropriate dilution, 20. Mu.L of samples were taken and the serotonin 5-HT and dopamine concentrations were measured by HPLC-ECD, a high performance liquid chromatography-electrochemical detection system. The potential of the glassy carbon working electrode was set at + -650 mV relative to an Ag/AgCl reference electrode at room temperature. Containing 0.1M NaH 2 PO 4 Mobile phase H for 8% methanol, 0.74mM SOS (1-octanesulfonic acid sodium salt), 0.03mM EDTA and 2mM KCl 3 PO 4 The pH was adjusted to 3.74 and the diluted filtrate was then injected into the chromatographic system at a flow rate of 0.2 mL/min. The concentration of the standard for determining 5-HT and dopamine concentrations in the samples ranged from 1-100ng/mL (Sigma-Aldrich, USA).
As shown in fig. 6, compared with CTL group, we detected that dopamine and 5-HT content in mice of MC group was significantly reduced, i.e. mice were depressed, and mood was lowered with reduced neurotransmitter content, whereas after supplementing probiotics, the neurotransmitter dopamine and 5-HT activity in mice were significantly improved, and it can be speculated that probiotics entered the gastrointestinal tract of mice through oral supplementation, could act on the cerebral nervous system of mice, and increase the content of important neurotransmission substances dopamine and 5-HT in the organism, thereby regulating mood, sleep, cognition, appetite, libido and other functions, i.e. the probiotic agent of the present invention could improve mood problems such as depression, anxiety and the like by modulating intestinal-brain axis. And the combination of the BL21 strain and the LC24 strain was more pronounced in the above efficacy compared to the single strain (data were statistically analyzed using the R language (R4.2.2) ggplot2 function, representing p <0.0001, representing p <0.001, and representing p <0.05 compared to the model MC group).
The applicant states that the present invention is illustrated by the above examples as a probiotic agent for improving mental diseases caused by environmental pollution by modulating the intestinal-brain axis and its application, but the present invention is not limited to the above examples, i.e. it does not mean that the present invention must be practiced depending on the above examples. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.
Claims (9)
1. A probiotic for improving mental diseases caused by environmental pollution by regulating intestinal-brain axis is characterized in that the strain in the probiotic comprises Bifidobacterium longum with a preservation number of CGMCC No.10452Bifidobacterium longum BL21 strain and lactobacillus paracasei with preservation number of CGMCC No.24411Lactobacillus paracasei LC24 strain.
2. The probiotic according to claim 1, characterized in that the psychotic disorder is anxiety or depression.
3. The probiotic according to claim 1, characterized in that in the probiotic, the bifidobacterium longumBifidobacterium longum BL21 strain with viable count not less than 5×10 9 CFU/mL。
4. The probiotic according to claim 1, characterized in that the bifidobacterium longumBifidobacterium longum BL21 strain and Lactobacillus paracaseiLactobacillus paracasei The ratio of the viable count of LC24 strain is 1:5-5:1.
5. The probiotic according to claim 1, wherein the formulation of the probiotic comprises a lyophilized powder, a capsule, a tablet or a granule.
6. The probiotic according to claim 1, characterized in that the probiotic further comprises lyoprotectants and/or functional adjuvants.
7. The probiotic according to claim 6, characterized in that the lyoprotectant comprises any one or a combination of at least two of skim milk, gelatin, dextrin, acacia, dextran, sodium alginate, polyvinylpyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol.
8. The probiotic according to claim 6, characterized in that the functional auxiliary agent comprises any one or a combination of at least two of fructooligosaccharides, galactooligosaccharides, xylooligosaccharides, isomaltooligosaccharides, soy oligosaccharides, inulin, spirulina, arthrospira, coriolus versicolor polysaccharides, stachyose, polydextrose, alpha-lactalbumin or lactoferrin.
9. Use of a probiotic according to any one of claims 1-8 in the manufacture of a medicament for the prevention, alleviation or treatment of psychotic disorders caused by metal arsenic contamination; the mental disorder is anxiety or depression.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310249024.XA CN116509902B (en) | 2023-03-15 | 2023-03-15 | Probiotic agent for improving mental diseases caused by environmental pollution by adjusting intestinal-brain axis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310249024.XA CN116509902B (en) | 2023-03-15 | 2023-03-15 | Probiotic agent for improving mental diseases caused by environmental pollution by adjusting intestinal-brain axis and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116509902A CN116509902A (en) | 2023-08-01 |
| CN116509902B true CN116509902B (en) | 2023-11-21 |
Family
ID=87405438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310249024.XA Active CN116509902B (en) | 2023-03-15 | 2023-03-15 | Probiotic agent for improving mental diseases caused by environmental pollution by adjusting intestinal-brain axis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116509902B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117887646B (en) * | 2024-03-18 | 2024-05-14 | 微康益生菌(苏州)股份有限公司 | Composite probiotics for resisting anxiety and depression and application thereof |
| CN118222462B (en) * | 2024-05-24 | 2024-09-24 | 微康益生菌(苏州)股份有限公司 | Probiotic combination for relieving depression or anxiety behaviors and application thereof |
| CN118440875B (en) * | 2024-07-08 | 2024-11-01 | 微康益生菌(苏州)股份有限公司 | Compound probiotics for resisting helicobacter pylori infection and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106399163A (en) * | 2016-09-08 | 2017-02-15 | 江苏微康生物科技有限公司 | Anti-aging probiotic preparation and preparation method thereof |
-
2023
- 2023-03-15 CN CN202310249024.XA patent/CN116509902B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106399163A (en) * | 2016-09-08 | 2017-02-15 | 江苏微康生物科技有限公司 | Anti-aging probiotic preparation and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| Reclassification of Bacillus beijingensis Qiu et al. 2009 and Bacillus ginsengi Qiu et al. 2009 as Bhargavaea beijingensis comb. nov. and Bhargavaea ginsengi comb. nov. and emended description of the genus Bhargavaea;Pankaj Verma等;nternational Journal of Systematic and Evolutionary Microbiology;第62卷;第2495-2504页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116509902A (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116509902B (en) | Probiotic agent for improving mental diseases caused by environmental pollution by adjusting intestinal-brain axis and application thereof | |
| CN110066753B (en) | Lactobacillus plantarum DP189 and its application | |
| CN109628359B (en) | A strain of Lactobacillus reuteri that can relieve allergic asthma and its application | |
| CN110643542B (en) | Lactobacillus reuteri capable of relieving Th2 reaction of allergic asthma and application thereof | |
| KR20150133646A (en) | COMPOSITION COMPRISING EXTRACELLULAR VESICLES DERIVED FROM Akkermansia muciniphila AS AN ACTIVE INGREDIENT FOR TREATING OR PREVENTING METABOLIC DISEASE | |
| WO2025030991A1 (en) | Bifidobacterium longum subsp. infantis capable of relieving parkinson's disease and use thereof | |
| CN117286077B (en) | Probiotics for preventing and treating acute radioactive intestinal injury and application thereof | |
| CN116970530B (en) | Bifidobacterium breve FPHC4024 for preventing and treating infantile diarrhea and application thereof | |
| US20240382539A1 (en) | Use of intestinal probiotic in preparation of medicament that promotes metabolism of ellagic acid into urolithin a, pharmaceutical composition and use thereof | |
| US20230346856A1 (en) | Bifidobacterium brevis and its application in preventing or alleviating psoriasis thereof | |
| WO2024061169A1 (en) | Use of prevotella in prevention and treatment of attention deficit-hyperactivity disorder | |
| CN116474002A (en) | Use of akkermansia muciniphila for alleviating and treating psychotic disorders | |
| CN116585360B (en) | Probiotic agent for improving chronic kidney disease and application thereof | |
| CN107496467A (en) | Purposes of the ovum spore Aode mushroom extract in the preparation for the treatment of and/or intestinal bacilli illness relevant disease is prepared | |
| Wojciechowska et al. | The gut microbiome meets nanomaterials: exposure and interplay with graphene nanoparticles | |
| CN111904983B (en) | Use of Bacillus licheniformis for the manufacture of a drug for the relief of mental illness | |
| CN114933992A (en) | Application of Bifidobacterium longum and its compound preparation in relieving ulcerative colitis | |
| CN109364097B (en) | Application of guar gum in the preparation of antidepressant drugs | |
| CN118406622B (en) | Probiotic agent for improving depression or anxiety and application thereof | |
| CN118389369B (en) | Probiotics containing mucin-philin Acremonium Akk strain for improving Alzheimer's disease and application thereof | |
| CN116656549B (en) | Probiotic capable of improving sleep quality and application thereof | |
| CN114642684B (en) | Eubacterium rectum (Eubacterium rectale) for preventing and treating anxiety depression | |
| CN117965398B (en) | Composite probiotics with mood stabilization effect and application thereof | |
| CN118147021B (en) | Composite probiotics for relieving gouty arthritis and application thereof | |
| CN111317746B (en) | Application of a kind of fullerene structure in the preparation of medicine for treating Alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |